Clinical Trials | June 02, 2026
Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
Fertility platform launches flagship clinic with advanced IVF tech
The approval is supported by results from the Phase 3 SWOG 1826 trial
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide
The company is building a connected healthcare ecosystem that utilises smart healthcare kiosk and mobile app to deliver at-home, AI-assisted health screenings and non-invasive health measurements
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
